Vitamin A

證據等級: L5

預測適應症: 10 個

Vitamin A: From Nutritional Deficiency to Prevention of Mortality/Morbidity in Very Low Birth Weight Preterm Infants

One-Sentence Summary

Vitamin A (retinol, DB00162) is an essential fat-soluble nutrient used to prevent and treat vitamin A deficiency. Among 10 TxGNN-predicted indications screened for this drug, the strongest-supported candidate is use in very low birth weight (VLBW) preterm infants to reduce mortality and short/long-term morbidity — including bronchopulmonary dysplasia (BPD) — with 5 iterations of Cochrane systematic reviews (2000–2016) and multiple large Phase 3 trials (including a 100,000-participant RCT) supporting this direction. The other 9 candidates identified by the model (e.g. “congenital prothrombin deficiency,” “biotin metabolic disease”) were assessed at L4–L5 evidence with a Hold recommendation due to weak, absent, or likely spurious knowledge-graph associations, and are not carried forward in this report.

Quick Overview

Item	Content
Original Indication	Vitamin A deficiency (essential nutrient supplementation) — not documented in SAHPRA licensing data, as the product is currently unregistered in South Africa
Predicted New Indication	Perinatal disease — specifically, prevention of mortality/morbidity (incl. bronchopulmonary dysplasia) in very low birth weight preterm infants
TxGNN Prediction Score	99.63%
Evidence Level	L1
South Africa Market Status	Not Marketed
Number of SAHPRA Registrations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this evidence pack. Based on known pharmacology, Vitamin A (retinol) and its active metabolites (retinoids) are required for epithelial cell differentiation, immune function, and normal lung and alveolar development. Its efficacy in preventing and treating vitamin A deficiency is well established, and mechanistically it may support respiratory epithelial maturation and alveolar septation — processes central to healthy lung development in the perinatal period.

Preterm infants, particularly VLBW infants, are born with low hepatic vitamin A stores and low retinol-binding protein levels. This deficiency has been associated with increased risk of chronic lung disease/bronchopulmonary dysplasia. Supplementing vitamin A during this critical developmental window is intended to restore adequate status and support lung tissue repair and maturation.

Importantly, this is not a novel indication expansion but an already well-documented area of neonatal clinical practice — the Cochrane Collaboration has published and updated a dedicated systematic review on this exact question five times (2000, 2002, 2007, 2011, 2016), each reaching consistent conclusions. The TxGNN label “perinatal disease” is broad; the actual supported use is this specific, narrow neonatal population, not perinatal disease in general.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00211341	Phase 3	Completed	100,000	Randomised, double-blind, placebo-controlled trial of weekly vitamin A supplementation (7000 µg RE) in reproductive-age women, Ghana; evaluated impact on maternal and perinatal mortality
NCT00133744	Phase 3	Completed	18,962	Iron/folic acid vs. multi-micronutrient (incl. vitamin A) vs. folic acid alone during pregnancy; primary outcome perinatal mortality, China
NCT00860470	Phase 3	Completed	44,567	Antenatal multiple-micronutrient (incl. vitamin A) supplementation to improve infant survival and health, Bangladesh
NCT00197743	Phase 3	Completed	1,085	Multivitamin (incl. vitamin A) supplementation in HIV-infected pregnant women, Tanzania; evaluated disease progression and maternal/infant health
NCT01404416	N/A	Completed	17,000	Post-trial follow-up of NCT00133744 assessing long-term child health outcomes after antenatal micronutrient supplementation
NCT01115478	N/A	Completed	2,500	Zinc and/or vitamin A supplementation in pregnancy; evaluated efficacy in reducing placental malaria and associated adverse pregnancy outcomes
NCT00168688	Phase 1	Completed	2,100	Prenatal multi-micronutrient (incl. vitamin A) supplementation vs. iron/folic acid; effects on birth weight and perinatal mortality, Guinea-Bissau
NCT03971604	N/A	Unknown	300	Correlation between vitamin A/E serum levels and preeclampsia risk

Note: No South African SANCTR or PACTR-registered trials were identified for this indication in the evidence pack.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
27552058	2016	Review (Cochrane)	Cochrane Database of Systematic Reviews	Latest update: vitamin A supplementation is associated with reduced risk of death or oxygen requirement at 1 month in VLBW infants; modest reduction in chronic lung disease. Five sequential Cochrane updates (2000, 2002, 2007, 2011, 2016) reach consistent conclusions
25222155	2014	Review	JAMA Pediatrics	Vitamin A shortage/deficiency at birth is linked to increased risk of bronchopulmonary dysplasia in preterm infants
22742601	2012	Systematic Review / Meta-analysis	Paediatric and Perinatal Epidemiology	Vitamin A and carotenoid supplementation during pregnancy and effects on maternal, neonatal, and infant health outcomes
23445845	2013	Review	The Journal of Pediatrics	Vitamin A and D status in preterm/low birth weight infants; risk of deficiency-related complications and need for supplementation
17952233	2007	Burden-of-disease study	S Afr Med J	Estimates the burden of disease attributable to vitamin A deficiency in children (0–4 yrs) and pregnant women in South Africa, 2000 — directly relevant to local context
2672772	1989	Review	Am J Clin Nutrition	Retinol stores are low at birth in premature infants; describes rationale for parenteral vitamin A supplementation
31771174	2019	Review	Nutrients	Perinatal undernutrition and its effects on metabolic hormones and lung development
15969267	2004	Observational/Prospective	Arch Latinoam Nutr	Serum vitamin A levels during pregnancy and obstetric/perinatal outcomes in HIV-infected pregnant women — relevant given South Africa’s HIV burden
9524850	1998	Review	Clin Infect Dis	Vitamin A/carotenoid status in HIV-infected persons; hyporetinemia associated with increased mortality risk, reversible with supplementation
29895848	2018	Case report	Eur J Clin Nutrition	Vitamin A and micronutrient deficiency complications across a complex multiparous pregnancy post-bariatric surgery

South Africa Market Information

Vitamin A currently has no SAHPRA product registrations and is classified as Not Marketed in South Africa in this evidence pack. No dosage form, brand, or approved indication text is available to report. Any clinical use for this indication would require either import under Section 21 authorisation or formal SAHPRA registration before routine use.

Safety Considerations

Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Five sequential Cochrane systematic reviews and multiple large Phase 3 trials consistently support vitamin A supplementation to reduce mortality and morbidity (including bronchopulmonary dysplasia) in very low birth weight preterm infants — meeting L1 evidence criteria. However, this supported use is a narrow neonatal-care population, not the broad “perinatal disease” label TxGNN assigned, and the product is not currently registered or marketed in South Africa.

To proceed, the following is needed:

SAHPRA/TFDA-approved Professional Information (PI) warnings, contraindications, and hypervitaminosis A safety data (currently a Blocking data gap)
Formal mechanism of action documentation via DrugBank or equivalent source (High-priority data gap)
Confirmation of a registration or Section 21 import pathway for parenteral/high-dose vitamin A formulations suitable for neonatal use
A population- and dose-specific clinical protocol for VLBW infants (dosing regimens vary substantially across the cited trials)
Clarification that the TxGNN “perinatal disease” label maps specifically to this VLBW/BPD-prevention use case, to avoid over-generalizing to unrelated perinatal conditions
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.